Real-world evidence for the effectiveness, safety and tolerability of Ribociclib + aromatase inhibitor in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer
Latest Information Update: 09 Dec 2023
At a glance
- Drugs Ribociclib (Primary) ; Anastrozole; Exemestane; Fulvestrant; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms RIBANNA
- 24 Oct 2023 Results of 5th interim analysis ( n=1377, At data cutoff Sep 6, 2022) assessing the efficacy, safety, and tolerability for elderly patients, presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Interim Results presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Interim Results (At data cutoff Sep 6, 2022, n=2581) assessing therapy management for RIB, including therapy-related adverse events (AEs), dose adjustment, and efficacy outcomes in special subgroups presented at the 48th European Society for Medical Oncology Congress